Diabetic Under 70 (Diabetics Below 70)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2009 by AstraZeneca.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00516204
First received: August 14, 2007
Last updated: January 21, 2009
Last verified: January 2009
  Purpose

A screening project of diabetics with a very high cardiovascular risk (e.g. diabetes plus coronary heart disease) who already receive cholesterol-lowering therapy. Lipid profile and rate of patients who are treated to target (which is <70mg/dl for such patients with very high risk) are screened. The doctors therapy decisions after the screening will be documented and 8-10 weeks later the lipid profile of each patient will be evaluated again. Our aim is to evaluate dosing habits, to evaluate how many patients are treated to their LDL-C target and to underline the importance of treating patients to their cholesterol targets.


Condition Intervention
Diabetes
Hyperlipidemia
Atherosclerosis
Drug: Any cholesterol-lowering drug

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Diabetic Under 70 (Diabetics Below 70)

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Estimated Enrollment: 1400
Study Start Date: July 2007
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diabetics with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PAVK, etc.) who already receive cholesterol-lowering therapy

Exclusion Criteria:

  • Diabetics w/o CVD; diabetics who do not receive cholesterol-lowering therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00516204

Locations
Austria
Research Site
Vienna, Austria
Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Michael Roden, MD Chairs of the Austrian Diabetes Society
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00516204     History of Changes
Other Study ID Numbers: NIS-CAT-CRE-2007/3
Study First Received: August 14, 2007
Last Updated: January 21, 2009
Health Authority: Not required for this study:

Keywords provided by AstraZeneca:
Hyperlipidemia
Diabetics
NIS
Diabetics with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PAVK, etc.)

Additional relevant MeSH terms:
Atherosclerosis
Hyperlipidemias
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Lipid Regulating Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 10, 2014